HugoScore hugoscore.org

Full review

Outcomes4Me CAIHL draft report

Evidence-linked HugoScore draft report for a health AI tool that affects patients.

Agency checklist · October 30, 2026

Mixed 5 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Outcomes4Me patient-facing cancer navigation and clinical trial discovery app; life-sciences business and Realyze clinical-workflow trial matching not assessed as the patient function

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Not independently replicated
uses Artificial Intelligence to translate that information so you can understand it Source

From the App Store description. Terms of Service and Privacy Policy do not mention AI. In-app disclosure or consent not verified.

2. Operator and model maker namedNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Outcomes4Me Inc. is named as operator. No source names an AI model or its maker.

3. Patient chooses to use itYesdocumented
Not independently replicated
Outcomes4Me is a direct-to-patient, AI-driven patient empowerment platform Source

Patient downloads and registers ('direct-to-patient'). Realyze (acquired May 2026) embeds AI trial matching in clinical workflows, a separate deployment.

4. Patient sets the taskNodocumented
Not independently replicated
display sponsored content to you, including to inform you of relevant clinical trials and available treatments offered by our partners Source

Consumer health data policy section 'For Sponsored Education'. For Life Sciences page markets 'lead generation' and sponsored content inside patient interactions. Operator steers toward partner goals.

5. Patient can decline or stopYesdocumented
Not independently replicated
Outcomes4Me is a direct-to-patient, AI-driven patient empowerment platform Source

Self-started rule applied (cites question 3 source). Privacy: users can use the Site without providing Personal Data.

6. Patient sees the AI outputYesdocumented
Not independently replicated
View treatment options and trials personalized to your diagnosis Source

Patient sees treatment options and trial matches in the app.

7. Patient can correct or challengeNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Privacy lets users update Personal Data (corrects inputs). No route to correct or contest the AI-generated treatment or trial output is documented.

8. Patient can get a copyNodocumented
Not independently replicated
Confirm whether we are collecting, sharing, or selling your consumer health data, and to access your consumer health data Source

Request route: [email protected]. Right is 'depending on your location'. Borderline, see caveats.

9. Patient can deleteYesdocumented
Not independently replicated
You may also request that we terminate your account and delete your Personal Data at any time. Source

Main privacy policy; unconditional wording.

10. Training or sale does not override patient choiceNodocumented
Not independently replicated
we may share this aggregated and/or de-identified data with our affiliates, agents and business partners Source

Terms license User Content 'as aggregated and/or de-identified for any lawful purpose'. Consumer health data policy: research partners include pharmaceutical companies. Withdrawal of consent is location-dependent. No AI-training statement either way.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted app only.

12. No advertising or data businessNodocumented
Not independently replicated
We also may use and share consumer health data to serve and load ads and other sponsored content on certain parts of our Services. Source

Also For Life Sciences page: real-world data, sponsored content and trial recruitment sold to pharma partners. Main privacy policy says 'not in the business of selling your Personal Data'; the health-data policy and Life Sciences page document the business. Answered by the more specific binding policy.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier report

Outcomes4Me: CAIHL reassessment

September 8, 2026. Published AI-assisted draft.

Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.

Scope and agency posture

Patient cancer navigation and trial discovery, with a separately disclosed life-sciences business. The two sets of interests coexist.

Posture: Mixed, strong patient education with sponsor-funded routing caveats.

Axis: 62/100, retained provisionally. No numerical recalibration was performed.

Sources and documented findings

  • The current life-sciences page sells precision marketing, sponsored education, lead generation and recruitment packets. Its example labels a prompt Sponsored. This establishes commercial influence channels, not evidence that treatment ranking is purchased. https://outcomes4me.com/for-life-sciences/
  • The health policy permits health-data-based sponsored content, advertising and research use. It requires express authorization for name/contact sharing with research partners and describes consent for advertising-partner sharing, plus access, deletion and withdrawal requests. https://static.outcomes4me.com/health/

Patient authority

Inference from the documented workflow: The historical patient workflow lets people seek treatment information and trials. The current sponsor offering establishes a competing conversion objective, but does not demonstrate patients losing their final choice.

Critical capacity

Editorial assessment: Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.

Informed control

Editorial assessment: Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.

Assessment and limits

Mixed remains supported by a specific sponsor-content mechanism alongside patient education. Avoid turning a business-model concern into an unproven allegation of biased recommendations.

Confidence: Moderate for disclosed purposes and commercial offering.

Remaining uncertainty: Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified

Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.

Review provenance

  • Reviewer/model: OpenAI Codex / GPT-6.
  • Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
  • Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
  • Earlier review: 2026-06-10. Historical assessment. Earlier claims are not automatically reverified by this publication.